Does Blue Cross Blue Shield Cover Orencia?
The verdict
Covered on most plans
BCBS plans cover Orencia with prior authorization and step therapy, but which benefit rail — pharmacy or medical — depends on the form of Orencia prescribed. Subcutaneous Orencia is a self-injected specialty drug on the pharmacy-benefit tier (Part D for Medicare, specialty tier for commercial). IV-infusion Orencia is a clinic-administered biologic billed under the medical benefit (J-code, like a procedure). Both require PA; both typically require trying preferred biologic DMARDs (adalimumab biosimilar, Enbrel) first for RA or PsA. Because BCBS is a federation of 30-plus independent licensees, verify the specific coverage rules on your state BCBS plan.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield using your member ID.
Key facts
Orencia's SC (subcutaneous) form runs through the pharmacy benefit (specialty tier, Part D for Medicare); the IV-infusion form runs through the medical benefit as a clinic-administered service — two forms, two benefit rails, two different cost-share structures.
Bristol Myers Squibb Orencia prescribing information; CMS benefit-design guidance
BCBS is a federation of 30-plus independent licensees — there is no single national BCBS Orencia policy; tier placement, preferred biologic step therapy, and PA criteria vary by state plan.
Blue Cross Blue Shield Association licensee information; individual BCBS state plan medical policy pages
The 2026 Medicare Part D out-of-pocket cap of $2,100 applies to SC Orencia covered on the Part D specialty tier; IV Orencia is covered under Part B where the cap does not apply — the Part B coinsurance structure applies instead.
CMS 2026 Part D benefit parameters; Medicare Part B drug coverage guidance
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield covers Orencia depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare: Orencia's benefit rail depends on form. SC (subcutaneous self-injection) — covered under Medicare Part D on the specialty tier; PA and step therapy required; 25–33% coinsurance after the deductible; the $2,100 (2026) Part D out-of-pocket cap limits annual exposure; manufacturer copay support is NOT available to Medicare beneficiaries. IV infusion — covered under Medicare Part B as a clinic-administered medical benefit; coinsurance is typically 20% of the Medicare-approved amount after the Part B deductible; Medigap supplement typically covers the 20%. BCBS Medicare Advantage and BCBS Medicare supplement plans handle the respective benefit rails; verify on your specific BCBS plan whether SC or IV is the expected form and what the PA criteria are.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: SC Orencia on the pharmacy-benefit specialty tier with PA and step therapy; IV Orencia under the medical benefit as a clinic-administered infusion with PA. Step therapy through preferred biologic DMARDs (typically an adalimumab biosimilar or Enbrel) for RA and PsA before Orencia is approved. Specific tier, step-therapy requirements, and preferred biologic sequence vary by BCBS licensee and PBM relationship. ACA/Individual: SC covered with PA where offered; SC/IV benefit split applies. Medicaid: BCBS-managed Medicaid covers Orencia per state PDL with PA; IV may be billed under a procedure code in some states. Verify on your specific state BCBS medical and pharmacy policy.
The 4 boxes you must tick to get approved
Commercial plans that will consider Orencia require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Orencia actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
Orencia is a high-cost specialty biologic. Precise list-price figures were not available in our research — use your plan's formulary cost estimator or GoodRx for a current estimate. Costs vary significantly by form (SC vs. IV) and site of care.
List price with no coverage — before any manufacturer savings card.
With coverage
SC (pharmacy benefit) commercial: 25–33% specialty coinsurance after deductible; varies by BCBS licensee. SC Medicare Part D: 25–33% coinsurance, capped by the $2,100 (2026) OOP cap. IV (medical benefit) Medicare: 20% Part B coinsurance after the Part B deductible; Medigap typically covers the 20%. Commercial IV: medical-benefit coinsurance per BCBS licensee plan design. Verify your specific cost-share with your BCBS plan.
Typical monthly copay once prior authorization is approved.
Bridge program
Bristol Myers Squibb's Orencia Co-Pay Assistance Program may be available to commercially insured patients for SC Orencia. Medicare and Medicaid beneficiaries are NOT eligible for manufacturer copay assistance. Verify eligibility directly with BMS.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share depends on your specific BCBS state plan, form of Orencia, and site of care. Verify on your BCBS plan's drug and medical-benefit formulary or by calling member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your specific BCBS state plan and look up its Orencia policy
There is no single national BCBS Orencia rule — each of the 30-plus BCBS licensees writes its own medical and pharmacy policy. Log in to your member account at your state BCBS website (e.g., anthem.com, bcbsil.com, bcbsnc.com, etc.) and search for the abatacept or Orencia policy in the medical or pharmacy section. Check both the drug formulary (for SC coverage) and the medical policy (for IV coverage).
- 2
Discuss the SC vs. IV form with your prescriber before the PA is submitted
The form of Orencia your rheumatologist prescribes determines which benefit rail is used. SC is a weekly self-injection covered under the pharmacy benefit; IV is an infusion administered in a rheumatology office or infusion center covered under the medical benefit. Different cost-share structures apply — your prescriber can advise which form is clinically appropriate and which may have more favorable coverage on your specific BCBS plan.
- 3
Confirm step-therapy requirements and submit PA with full biologic history
Ask your prescriber to check the PA criteria for your specific BCBS plan. Most BCBS plans require trying a preferred biologic DMARD (usually an adalimumab biosimilar or Enbrel) first. Submit the PA with documentation of your diagnosis, prior biologic or conventional DMARD trial history, and the specific Orencia form requested. Approval is typically 12 months; confirm the reauthorization schedule with your prescriber.
Options if Blue Cross Blue Shield won't cover Orencia
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Adalimumab biosimilar (Amjevita, Hyrimoz, Hadlima, or others)
Often required as a step-therapy prior to Orencia for RA and PsA on BCBS plans. Pharmacy-benefit specialty drug (PA required). Multiple FDA-approved adalimumab biosimilars are available; the preferred biosimilar depends on your specific BCBS plan's PBM.
Enbrel (etanercept)
TNF inhibitor biologic DMARD; typically a required step-therapy agent before Orencia on many BCBS plans for RA, PsA, and ankylosing spondylitis. No marketed biosimilar until 2029 (blocked by patent litigation). Specialty tier with PA.
Cosentyx (secukinumab)
IL-17 biologic for RA (in some plans), PsA, and ankylosing spondylitis. Pharmacy-benefit specialty drug with PA and step therapy. Unlike Orencia, Cosentyx is only available as a subcutaneous injection and does not have a dual SC/IV benefit-rail option.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Both — the benefit rail depends on the form. Subcutaneous Orencia (weekly self-injection at home) is a pharmacy-benefit specialty drug covered under Part D for Medicare or the commercial drug formulary. IV Orencia (weight-based infusion at a clinic or infusion center) is covered under the medical benefit as a clinician-administered service. Each form has different cost-share structures, PA processes, and potentially different coverage criteria at your specific BCBS plan.
Yes, most BCBS licensees require prior authorization and step therapy through preferred biologic DMARDs before Orencia is approved for RA or PsA. This typically means documenting trial and failure of an adalimumab biosimilar or Enbrel first. Exact step-therapy requirements vary by BCBS licensee and indication — verify on your specific state BCBS plan's clinical criteria for abatacept/Orencia.
For SC Orencia on Medicare, coverage runs under Part D on the specialty tier — 25–33% coinsurance, capped by the $2,100 (2026) OOP cap. For IV Orencia on Medicare, coverage runs under Part B as a medical benefit — 20% coinsurance after the Part B deductible; a Medigap supplement or BCBS Medicare Advantage plan copay may cover or reduce the 20%. The specific benefit structure depends on your BCBS Medicare plan; verify with your BCBS plan documents.
There is no single national BCBS Orencia policy. BCBS is a federation of 30-plus independent state-level licensees, each writing its own medical and pharmacy policies. Independence Blue Cross, BCBS of North Carolina, Blue Shield of California, and Anthem/Elevance (a BCBS licensee in 14 states) all have separate policies. The general pattern — covered with PA, step therapy, SC/IV benefit split — holds across most, but tier, preferred products, and step-therapy details vary. Check your specific state BCBS plan.
Bristol Myers Squibb's Orencia copay assistance may be available to commercially insured BCBS patients for SC Orencia. Medicare and Medicaid beneficiaries are NOT eligible for manufacturer copay support under federal anti-kickback rules. If you have BCBS commercial insurance, verify eligibility for the BMS Co-Pay Assistance Program directly with Bristol Myers Squibb before filling your first prescription.
Related Articles
Does BCBS Michigan Cover Contrave? 2026 MI Guide | Curex
BCBS Michigan upheld weight-loss exclusions (DIFS 2025). Contrave is plan-dependent. MI Medicaid favors weight-loss GLP-1s; Contrave varies by PDL.
Read moreDoes BCBS of Illinois Cover Jardiance? 2026
BCBS of Illinois (HCSC) covers Jardiance across commercial, ACA, Medicare, and Medicaid. Metformin-first step is common. 2026 MFP $197 for Medicare.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Ambien? 2026 | Curex
Blue Cross Blue Shield covers generic zolpidem (Tier 1–2); brand Ambien is non-preferred. Quantity limits apply. Verify your specific BCBS plan for 2026.
Read moreDoes BCBS of Texas Cover Ozempic? 2026 Guide | Curex
BCBS Texas (HCSC) covers Ozempic for T2D with PA — not weight loss. HCSC shares PA with BCBS IL. TX Medicaid uses separate Star MCOs. Verify on BCBS TX.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.